465 filings
Page 5 of 24
8-K
bh2 x50gt83o
15 Dec 20
Sio Gene Therapies Announces Positive Six-Month Follow-Up Data from Low-Dose Cohort of Phase 1/2 Trial of AXO-AAV-GM1 for GM1 Gangliosidosis
4:04pm
4
tazn4ncuy qwtww
25 Nov 20
Sio Gene Therapies / Atul Pande ownership change
9:07pm
EFFECT
6i81a f6a
20 Nov 20
Notice of effectiveness
12:15am
EFFECT
h3hv01wo425m3dcj8j
20 Nov 20
Notice of effectiveness
12:15am
S-8 POS
o1rbfw
13 Nov 20
Registration of securities for employees (post-effective amendment)
5:27pm
POS AM
dc626
13 Nov 20
Prospectus update (post-effective amendment)
5:05pm
POS AM
2czif7 hc
13 Nov 20
Prospectus update (post-effective amendment)
5:03pm
8-K12G3
zuqo20j 2phi4v
13 Nov 20
Notification of registration of securities
7:05am
8-K
sse5dn0cm9iaw
13 Nov 20
Results of Operations and Financial Condition
7:03am
EFFECT
o6dia958ethwevr2
13 Nov 20
Notice of effectiveness
12:15am
S-4/A
um9axc20b0abg88khblu
10 Nov 20
Registration of securities issued in business combination transactions (amended)
5:10pm
8-K
rpqkg1svukcg276 e6xx
10 Nov 20
Axovant Gene Therapies Announces Name Change to Sio Gene Therapies
7:02am
CORRESP
ziu13trkv79wobmc4
10 Nov 20
Correspondence with SEC
12:00am
8-K
xcbf ge8n
9 Nov 20
Axovant Gene Therapies Announces FDA Clearance of IND for AXO-AAV-GM2 Gene Therapy in Tay-Sachs and Sandhoff Diseases
7:00am
8-K
q7g 9ozlcyd7c
29 Oct 20
Regulation FD Disclosure
4:03pm
8-K
1f1ben0dbp9fwc17
13 Oct 20
Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM2 for Tay-Sachs and Sandhoff Disease
7:01am
8-K
v55r6 2ykkdf1t5fqxg
9 Oct 20
Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM1 for GM1 Gangliosidosis
7:00am
8-K
4f6gm ulccxwcns
8 Oct 20
Departure of Directors or Certain Officers
7:16am
UPLOAD
v43h3i8w
8 Oct 20
Letter from SEC
12:00am